Atyr_Logo.png
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
January 29, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma to present posters on the importance of Neuropilin-2 in immune regulation at the Keystone Symposia on Myeloid Cell Diversity.
Atyr_Logo.png
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
January 18, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease (ILD).
Atyr_Logo.png
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
November 13, 2023 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its...
Atyr_Logo.png
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
November 09, 2023 16:00 ET | aTyr Pharma, Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated...
Atyr_Logo.png
aTyr Pharma to Present at November Investor Conferences
November 01, 2023 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma announces that it will present at two investor conferences in November 2023.
Atyr_Logo.png
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
October 31, 2023 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma announces that it has dosed the first patient in its Phase 2 EFZO-CONNECT study of efzofitimod in patients with SSc-ILD.
Atyr_Logo.png
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
September 11, 2023 08:00 ET | aTyr Pharma, Inc.
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg...
Atyr_Logo.png
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 24, 2023 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
Atyr_Logo.png
aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
August 09, 2023 16:00 ET | aTyr Pharma, Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in the...
Atyr_Logo.png
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic Sclerosis
June 22, 2023 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...